Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cocrystal Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COCP
Nasdaq
2834
www.cocrystalpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cocrystal Pharma, Inc.
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch
- Feb 11th, 2025 8:11 pm
COCP: Phase 2a Trial of CC-42344 Extended…
- Jan 8th, 2025 1:05 pm
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
- Jan 8th, 2025 1:00 pm
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial
- Jan 2nd, 2025 11:34 am
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement
- Dec 31st, 2024 7:03 pm
Top Midday Decliners
- Dec 31st, 2024 6:21 pm
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
- Dec 31st, 2024 1:00 pm
US Penny Stocks To Watch In December 2024
- Dec 17th, 2024 8:07 pm
COCP: Multiple Upcoming Catalysts…
- Nov 19th, 2024 2:14 pm
November 2024 US Exchange Standouts: Promising Penny Stocks
- Nov 15th, 2024 12:09 am
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- Nov 13th, 2024 1:00 pm
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
- Oct 31st, 2024 12:00 pm
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation
- Oct 18th, 2024 10:45 am
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
- Sep 26th, 2024 12:00 pm
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
- Aug 19th, 2024 8:05 pm
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
- Aug 19th, 2024 1:15 pm
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
- Aug 15th, 2024 7:00 pm
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- Aug 14th, 2024 12:00 pm
COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…
- Jul 19th, 2024 1:11 pm
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
- Jul 18th, 2024 12:00 pm
Scroll